Subjects in the Lidocaine arm of the randomized trial will receive a bolus of 1 mg /Kg of IV lidocaine followed by 1.5 mg/KG/h of IV lidocaine infusion during the surgery which will be stopped at extubation.

Subjects in the Placebo arm of the randomized trial will receive a bolus of 1mg/kg Placebo ( 0.9% saline) followed by 1.5 mg/KG/h Placebo ( 0.9% saline) infusion during the surgery which will be stopped at extubation.

Thyroidectomy

Nerve Monitoring

Lidocaine

Placebo

Health and Wellness Center- Bronx Lebanon Hospital Center

Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring

Number of times laryngo tracheal reflexes were encountered during surgery will be recorded.

The total amount of each anesthesia medication used will be recorded

Pain will be measured on a scale of 1 to 10

The total amount of medications used to control pain will be recorded

Number of episodes of nausea and vomiting will be recorded

Comfort level will be measured on a scale of 1 to 10

Ramasamy Govindarajan

Clinical Research In-Charge, Anesthesia

Bronx-Lebanon Hospital Center Health Care System

Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis.

Migraine Prophylaxis

Histamine Dihydrochloride

Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis

Phase II Study to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis

Mean change from baseline in monthly migraine days [time frame: baseline and average over Weeks 3-22].

Mean change from baseline in monthly migraine days by 4 week intervals [Weeks 3-6, 7-10, 11-14, 15-18, 19-22].

Mean Change from Baseline in Monthly Migraine Index (MMI) [ Time Frame: baseline and average over observation period (Weeks 3-22).
Monthly Migraine Index (MMI):
Migraine headaches are assigned a number based on the peak intensity of that migraine headache:
1 for a mild migraine headache
2 for a moderate migraine headache
3 for a severe migraine headache.
The MMI is calculated as follows:
MMI= Sum of [(Migraine Peak Intensity Level (1-3)) x (Migraine Duration (hours))] / (Distinct Number of Migraine Headaches for that 4 week period)
Sample Calculation:
The patient experiences 3 migraine headaches (M1, M2, and M3) in 4 weeks . M1: Intensity Level 3, Duration is 7 hrs M2: Intensity Level 2, Duration 3 hrs M3: Intensity Level 3, Duration 15 hrs MMI= (3x7 + 2x3 + 3x15) / 3 = 24

Mean change from baseline in monthly number of migraines [time frame: baseline and over Weeks 3-22].

Mean change from baseline in monthly number of migraines by 4 week intervals [Weeks 3-6, 7-10, 11-14, 15-18, 19-22].

neurogenic inflammation/تقيؤ

Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم